CHINA LIFE (02628.HK) +0.640 (+1.935%) Short selling $76.95M; Ratio 25.746% opened a positive catalyst watch, as it is expected to deliver comprehensive FY2025 results and report strong new business value growth in 1Q26, Citi Research issued a research report saying.In addition, the broker estimated CHINA LIFE's management to provide more positive information regarding its 1Q26 new business value growth trend and long-term dividend policy at the FY025 results briefing. Related NewsCiti's Ratings & TPs for CN Insurers (Table)Therefore, the broker rated CHINA LIFE at Buy, with a target price of $40, expressing optimism about CHINA LIFE's renowned brand, extensive offline distribution network and its revitalization reform initiatives.(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-02-16 12:25.)